Tagged with generics

Poland Wojciech Sulimierski, general manager of Aspen Poland and CEE, discusses the opening of the regional operations in 2014 and the importance of the CEE region as the company establishes itself in the global pharmaceutical ecosystem. Moreover, he highlights the impact of global acquisitions and the niche area model they have…

Canada Ian Jacobson, CEO of Juno Pharmaceuticals, presents the company’s business model of in-licensing and repurposing generic products. He highlights the successful development of the company’s affiliates in Australia, the UK and South Africa, and his plans to refocus efforts on the Canadian market in the near future, aiming to launch…

Lithuania Audrius Tutlys, country manager at Teva Lithuania, highlights the importance of Teva in Lithuania, based not only on its broad product offering but also its manufacturing capabilities and shares his willingness to position Teva as a true partner of the government in making Lithuania a European biotech center. Can you…

Canada Madhu Venkat, CEO of Natco Pharma Canada, highlights the company’s portfolio strategy, its strategic road map to be the first mover and become a leading generic supplier in oncology by 2020. He further illustrates that to be successful in Canada, it pays off to be a niche player and vertically…

Lithuania Darius Sinkevičius, chairman of the board at the Lithuanian Association of Generic Pharmaceuticals Manufacturers (VGA), explains the main trends impacting the generic pharmaceutical industry in the country as well as the role of off-patent medicines in creating savings for the Lithuanian healthcare system. Can you give to our international audience…

India Indian pharma production is growing rapidly – boosted by the Modi government’s ‘Make in India’ campaign – and both Indian companies and multinationals implanted in the world’s second most populous nation are responding to the drastic need for quality, affordable generic medicines across the world. “When it comes to manufacturing…

Canada Michel Charbonneau, executive VP at Accord Healthcare Inc. touches upon the rapid evolution of the Canadian affiliate over the past five years, and the company’s commitment to bringing high-quality, innovative, affordable generics to patients. He furthermore expresses his hopes for collaboration between generic players in the Canadian pharmaceutical industry in…

Brazil Ricardo Lourenço, VP-Managing Director of Lupin in Brazil has been in charge of implementing the take over of Medquímica by Lupin. In this interview he explains Brazil is a land of many opportunities. He is looking forward to capitalize the fast growth rate of generic products in Brazil, revive the…

Canada Louis Pilon, president and CEO, highlights JAMP Pharma’s unique positioning as a Canadian generics company with one of the largest salesforce covering the whole Canadian market as well as the fourth-largest product portfolio, their focus on niche and complex products, their agility in seizing new opportunities, and his mission to…

Poland Michał Pietraszek, general manager of Apotex Poland, the leading Canadian generics powerhouse, discusses the affiliate’s strategic move into the OTC and food supplement business and the company’s niche-market approach to its Rx generics. Furthermore, he highlights the potential of Poland to be a key player within the company’s international success…

Canada Michel Robidoux, president and general manager of Sandoz Canada, charts the extremely successful journey for this Novartis division. He explains the strategy Sandoz Canada has undertaken to expand its portfolio in the four business segments of generics, biosimilars, consumer (OTC) and specialty products. He talks about the quality of the…

Canada Vinod Ramachandran, general manager of Dr. Reddy’s Canadian affiliate, highlights the exciting journey of Dr. Reddy’s in Canada since 2013, the company’s upcoming three specialty product launches, and the goal of Dr. Reddy’s to supply affordable and quality generic medicines. Vinod, you established the Dr. Reddy’s affiliate here four years…